TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11682582
Drug: 0.50 g
Normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 g of protein x kg(‐1) x day(‐1)
Study: 11682582
Drug: 0.75 g
Normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g of protein x kg(‐1) x day(‐1)
Study: 11682582
Drug: 1.00 g
Normalized name: Niacinamide 1.00 g in 50 mL TOPICAL LIQUID [by selected hyaluron day serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.00 g of protein x kg(‐1) x day(‐1)
Study: 2975291
Drug: Isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 10 mg
Study: 2975291
Drug: Isradipine 20
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine 20 mg
Study: 31342057
Drug: Outpatient parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient parenteral antimicrobial therapy plus buprenorphine treatment
Study: 31342057
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (inpatient intravenous antibiotic completion)
Study: 27477896
Drug: Placebo (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (24 mL saline solution)
Study: 23713304
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection at trigger points
Study: 18814407
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Simvastatin (universal use)
Study: 18814407
Drug: 0.5 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mmol/L reduction in total cholesterol
Study: 18814407
Drug: 1.0 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mmol/L reduction in total cholesterol
Study: 18814407
Drug: 1.5 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mmol/L reduction in total cholesterol
Study: 18814407
Drug: 2.0 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mmol/L reduction in total cholesterol
Study: 11147929
Drug: G(‐463)A polymorphism
Normalized name: Angelica polymorpha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: G(‐463)A polymorphism of myeloperoxidase (MPO) gene
Study: 1464895
Drug: Trandolapril 8
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril 8 mg
Study: 1464895
Drug: Trandolapril (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2, 4, 8 mg)
Study: 28668774
Drug: Repeat lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat lactate ≥ 5 mmol/L
Study: 26891150
Drug: 20% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% human albumin (100, 200, or 300 ml based on preoperative serum albumin level)
Study: 2077596
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of saline at 37 degrees C
Study: 231324
Drug: Phanurane (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phanurane (2 gelules daily, 2 X 50 mg of canrenone)
Study: 28192854
Drug: TRP agonist
Normalized name: Trp
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRP agonist
Study: 23621350
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg rBet v 1‐FV
Study: 23621350
Drug: 80 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 μg rBet v 1‐FV
Study: 23621350
Drug: 160 μg
Normalized name: immunoglobulin G, human 160 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 μg rBet v 1‐FV
Study: 23621350
Drug: 320 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 μg rBet v 1‐FV
Study: 22185606
Drug: Educational supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational supportive therapy in a group (placebo, 6 sessions)
Study: 22185606
Drug: Educational supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational supportive therapy in a group (placebo)
Study: 19422286
Drug: BEMER magnetic
Normalized name: Beser
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BEMER magnetic field treatment for 8 minutes twice daily for 12 weeks
Study: 15019375
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% and timolol 0.5% once daily
Study: 15019375
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% and timolol 0.5% twice daily
Study: 3493333
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (blind, placebo-controlled protocol)
Study: 3493333
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (double-blind, placebo-controlled protocol)
Study: 26584951
Drug: Levodopa/carbidopa 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 100/25 mg TID for 40 weeks (including 2 weeks of dose escalation)
Study: 26584951
Drug: Levodopa/carbidopa 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 100/25 mg TID for 40 weeks (after initial 40 weeks of treatment)
Study: 18779882
Drug: Dysport 200
Normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport 200 U/ml
Study: 18779882
Drug: Dysport 150
Normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport 150 U/ml
Study: 18779882
Drug: Dysport 100
Normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport 100 U/ml
Study: 18779882
Drug: Botox 100
Normalized name: Botox 100 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox 100 U/ml
Study: 16554494
Drug: Homozygous carriers
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homozygous carriers of the G-allele
Study: 10690944
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose epinephrine (0.375 microg/min)
Study: 10690944
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose epinephrine (0.75 microg/min)
Study: 10690944
Drug: Epinephrine studies
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine studies (both doses)
Study: 8191053
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy with Naftidrofuryl, 1 session per day
Study: 8191053
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy with Naftidrofuryl, 2 sessions per day
Study: 26027612
Drug: Cyclosporine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (2.5 mg/kg intravenous infusion)
Study: 23215966
Drug: Short treatment
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short treatment (three x two-hour sessions)
Study: 21415156
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at baseline
Study: 21415156
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin at baseline
Study: 2524684
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 27 mg plus ethinyl estradiol 0.035 mg/day
Study: 6210867
Drug: Danazol 600
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 600 mg/day
Study: 30957449
Drug: Bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion hydrochloride sustained-release tablets
Study: 29079252
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (HbA1c <6.2% [44.3 mmol/mol], blood pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a history of coronary artery disease])
Study: 29079252
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (targets: HbA1c <6.9% [52.0 mmol/mol], blood pressure <130/80 mm Hg, LDL cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary artery disease])
Study: 23239680
Drug: Milk supplementation
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplementation (24 oz/day, one 16-oz dose immediately post-RT)
Study: 21184185
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol fumarate (MF/F) combination
Study: 17270315
Drug: Eflornithine cream
Normalized name: eflornithine Topical Cream
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eflornithine cream plus laser treatment
Study: 17270315
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment alone (placebo cream)
Study: 11699049
Drug: Stress hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stress hormone infusion
Study: 3165436
Drug: Levodopa sustained-release
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa sustained-release (S. R.) formulations
Study: 3165436
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation of levodopa
Study: 28587581
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enalapril (E) for 4 weeks
Study: 28587581
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril (E) with or without hydrochlorothiazide (acute treatment)
Study: 28587581
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril (E) + 16 mg candesartan (EC) for chronic treatment
Study: 25246074
Drug: HA viscosupplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA viscosupplementation (3 weekly intra-articular injections of HA)
Study: 24168767
Drug: Frequent exacerbators
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent exacerbators (≥ 2 exacerbations during study treatment)
Study: 18430744
Drug: Lornoxicam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (0.1 mg kg(‐1))
Study: 11317154
Drug: Supplemented Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented Group (A) with SUPRO Isolated Soy Protein (1 g/kg body weight)
Study: 7696152
Drug: CYTOPRESS semi‐automatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYTOPRESS semi‐automatic slide preparation system and CERVIFIP interactive scanner
Study: 30309755
Drug: Cold tumescence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold tumescence anesthesia solution (4°C)
Study: 30309755
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature tumescence anesthesia solution (24°C)
Study: 27097858
Drug: Hypnosis prior
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis prior to local anesthesia administration
Study: 24366425
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight (HMW) urinary adiponectin excretion
Study: 24366425
Drug: HMW-adiponectin excretion
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMW-adiponectin excretion
Study: 24366425
Drug: Total adiponectin
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total adiponectin excretion
Study: 24366425
Drug: Albumin excretion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin excretion rate (AER)
Study: 22761709
Drug: Diltiazem sustained-release
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem sustained-release capsules (90 mg twice daily)
Study: 22761709
Drug: Diltiazem sustained-release
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem sustained-release capsules
Study: 22761709
Drug: Diltiazem sustained-release
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem sustained-release capsules and Placebo
Study: 7873474
Drug: Low-dose positive
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose positive inotropes (including vesnarinone)
Study: 25772326
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus concurrent oral vinorelbine and capecitabine
Study: 25772326
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus sequential oral vinorelbine and capecitabine
Study: 23397148
Drug: GLM 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLM 100 mg + MTX
Study: 23397148
Drug: GLM 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLM 50 mg + MTX
Study: 23397148
Drug: GLM 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLM 50 mg
Study: 23397148
Drug: GLM 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLM 100 mg
Study: 15488964
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ipsapirone orally
Study: 15488964
Drug: 0.002 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.002 mg/kg intravenous clonidine
Study: 15488964
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release venlafaxine (37.5 mg, b.i.d. for low-dose responders; 75 mg, b.i.d. or higher for high-dose responders)
Study: 10878071
Drug: stavudine-zalcitabine-saquinavir (soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: stavudine-zalcitabine-saquinavir (soft gel capsule) [d4T-ddC-SQV(SGC)]
Study: 9145450
Drug: Dietary fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fibre and lactulose biscuits (11 biscuits containing 10 g dietary fibre, 2 g raw fibre, 8.2 g lactulose)
Study: 27196764
Drug: FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI plus bevacizumab (first-line treatment)
Study: 20388497
Drug: Energy-free placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-free placebo solution (PLA)
Study: 18450787
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for 24 weeks
Study: 8828617
Drug: Low concurrent
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concurrent phenylalanine (Phe) levels
Study: 8828617
Drug: High concurrent
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concurrent phenylalanine (Phe) levels
Study: 8828617
Drug: Lowering concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering concurrent phenylalanine (Phe) levels over a period of 4-5 weeks
Study: 2996905
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg once daily (o.d.)
Study: 2996905
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg twice daily (b.d.)
Study: 28002896
Drug: Hybrid Hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hybrid Hyaluronic Acid (HHA); 3 injections
Study: 28002896
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP); 3 injections
Study: 7870676
Drug: PEG Ointment
Normalized name: sodium salicylate/peg ointment/butylated hydroxytoluene 2 %-0.2 % TOPICAL OINTMENT (GRAM)
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG Ointment tetracaine
Study: 3067252
Drug: Combined estrogen‐androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogen‐androgen preparation
Study: 2351625
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg intravenous dose of cefuroxime
Study: 2351625
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral dose of cefuroxime axetil
Study: 2351625
Drug: AUC0-6 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUC0-6 h after oral dosage
Study: 2351625
Drug: Abbreviated methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated methods of assessing bioavailability
Study: 30790345
Drug: GSK3008356 (DGAT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3008356 (DGAT1 inhibitor)
Study: 23268593
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 300 mg plus 100 mg dimethicone and water up to 100 ml
Study: 23268593
Drug: Dimethicone 100
Normalized name: dimethicone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethicone 100 mg (5 ml at 20 mg/ml) plus water up to 100 ml
Study: 21972619
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy combined with SSRI (observation group 1)
Study: 21972619
Drug: Electroacupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture therapy combined with SSRI (observation group 2)
Study: 16507185
Drug: Hyperbaric lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric lidocaine 20 mg and ropivacaine 5 mg (Group LR)
Study: 16507185
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine 10 mg (Group R)
Study: 15573335
Drug: Polyethylene glycol-electrolyte
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-electrolyte solution (PEG-ES)
Study: 8128430
Drug: Prednisone (P),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (P), 1 mg/kg for 3 weeks, followed by either continued P for an additional 6 weeks, tapering P and beginning cyclophosphamide (C), 2 mg/kg, or continuing P and adding C.
Study: 8128430
Drug: Cyclophosphamide (C),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (C), 2 mg/kg.
Study: 8128430
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Prednisone (P) and Cyclophosphamide (C).
Study: 27552517
Drug: AR-12286 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-12286 0.5% or 0.7% topical solution, administered once daily for 24 weeks.
Study: 18925316
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day for 4 weeks
Study: 16931936
Drug: TMC278 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 (25, 50, 100, or 150 mg once-daily for 7 days)
Study: 11768837
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg every 6 hours for a total of 7 doses
Study: 11768837
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg every 6 hours for a total of 7 doses
Study: 9832953
Drug: Intranasal heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal heroin (placebo, 12.5, 25, 50, 100 mg)
Study: 9832953
Drug: Intranasal heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal heroin (100 mg)
Study: 9832953
Drug: Intranasal heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal heroin (various doses)
Study: 9832953
Drug: Intranasal heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal heroin
Study: 7971646
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment (prednisone and azathioprine for 3 months)
Study: 23761484
Drug: ω‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFA supplementation (400 mg DHA daily)
Study: 22279783
Drug: Selzink medicine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selzink medicine, a one-month course of therapy
Study: 11097668
Drug: 1.2 mL
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mL (6 mg) of plain 0.5% bupivacaine (group 1; n = 30)
Study: 11097668
Drug: 1.2 mL
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mL (6 mg) of hyperbaric 0.5% bupivacaine in 8% glucose (group 2; n = 30)
Study: 8638546
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA)
Study: 8638546
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of 5-FU and HDFA plus low-dose alpha-2b interferon
Study: 1317694
Drug: Naproxen (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (loading dose, 400 mg or 500 mg followed by 200 mg or 500 mg three times daily for 5 days)
Study: 6543609
Drug: Morphine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2.5 mg/kg)
Study: 6543609
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/kg)
Study: 10464128
Drug: Azathioprine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (40 mg/kg loading dose followed by 2 mg/kg oral for 16 weeks)
Study: 9248904
Drug: Intramuscular sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular sumatriptan 6 mg
Study: 9248904
Drug: Intravenous chlorpromazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chlorpromazine, 12.5 mg increments to a maximum of 37.5 mg
Study: 1911008
Drug: Continuous i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.m. infusion of ketorolac 10 mg